Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guinó E, Durán G, Lamas MJ, López R, Candamio S, Gallardo E, Paré L, Baiget M, Páez D, López-Fernández LA, Cortejoso L, García MI, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé JM, Jover R, Brea-Fernández A, Andreu M, Bessa X, Llor X, Xicola R, Palles C, Tomlinson I, Castellví-Bel S, Castells A, Ruiz-Ponte C, Carracedo A. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. The Pharmacogenomics Journal 2012, 13: 209-217. PMID: 22310351, DOI: 10.1038/tpj.2012.2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, PharmacologicalClinical Trials, Phase II as TopicColorectal NeoplasmsDrug-Related Side Effects and Adverse ReactionsFemaleFluorouracilGenome-Wide Association StudyGenotyping TechniquesHumansLeucovorinMaleMiddle AgedOrganoplatinum CompoundsPharmacogeneticsPolymorphism, Single NucleotideTreatment OutcomeConceptsAdverse drug reactionsColorectal cancer patientsEvidence of associationFOLFOX administrationCRC patientsColorectal cancerCancer patientsDrug reactionsDrug AdministrationWide association studyPatientsVariable outcomesInter-individual variationAdministrationAssociation studiesGenome-wide scaleFirst studyWide screeningValidation setFOLFOXOxaliplatinGenetic basisCancer